The Corporation intends to continue to rely on the support of Neptune for a portion of its general and administrative needs; however, the continuance of this support is outside of the Corporation’s control. The Corporation was charged by Neptune for the purchase of research supplies and for certain costs incurred by Neptune for the benefit of the Corporation, as follows:

 

							Thirteen-months ended				Month ended				Twelve-months ended
			March 31, 2018				March 31, 2017				March 31, 2017				February 28, 2017				February 29, 2016
											(Unaudited)				(Unaudited)
			$				$				$				$				$
Research and development expenses
Supplies and incremental costs			7				-				-				-				5
Shared service agreement			20				60				1				59				366
Total			27				60				1				59				371
General and administrative expenses
Supplies and incremental costs			239				293				16				277				299
Shared service agreement			121				325				25				300				491
Total			360				618				41				577				790
Total related parties expenses			387				678				42				636				1,161

 

Where Neptune incurs specific incremental costs for the benefit of the Corporation, it charges those amounts directly. Neptune provides Acasti with the services of personnel for certain administrative work as part of a shared service agreement. The employees’ salaries and benefits are charged proportionally to the time allocation agreed upon within the shared service agreement. For the year ended laboratory support, the corporate affairs and the public company reporting services previously provided by Neptune as part of the shared service agreement were discontinued. The Corporation is now incurring incremental costs and expects to do so in the future, partially offset by reduced shared service fees. The account payable to Neptune amounted to at at and at is non-interest bearing and has specified maturity date. These charges do represent all charges incurred by Neptune that have benefited the Corporation. Also, these charges do necessarily represent the cost that the Corporation would otherwise need to incur, should it receive these services or benefits through the shared resources of Neptune.

 

Historically, Neptune has provided the Corporation with the krill oil needed to produce CaPre for Acasti’s clinical programs, including all of the krill oil projected as needed for its Phase clinical study program. However, Neptune discontinued its krill oil production and sold its krill oil inventory to Aker on During the period, Acasti purchased a reserve of krill oil from Aker that will be used in the production of CaPre capsules for its Phase clinical trials (see also note ). The Corporation is currently evaluating alternative suppliers of krill oil. At a reserve of krill oil was still stored at Neptune’s facility.

 

 

On Neptune announced the acquisition of Biodroga Nutraceuticals Inc. As part of this transaction, the Corporation pledged an amount of million (“Committed Funds”) to partly guarantee the financing for the said transaction (“Pledge Agreement”). Neptune had agreed to pay Acasti an annual fee on the Committed Funds outstanding at an annual rate of during the months and for the remaining term of the Pledge Agreement. On Neptune fully released the pledged amount. The Corporation recognized interest revenue of for the year ended and, for the -month period ended (unaudited) for the month ended and (unaudited) for the -month period ended and for the year ended

 

 

The key management personnel are the officers of the Corporation and the members of the Board of Directors of the Corporation. They control in the aggregate less than of the voting shares of the Corporation ( in and in ).

 

Key management personnel compensation includes the following for the year ended and the -month and -month periods ended -month period ended and year ended

 

							Thirteen- months ended				Month ended				Twelve- months ended
			March 31, 2018				March 31, 2017				March 31, 2017				February 28, 2017				February 29, 2016
											(Unaudited)				(Unaudited)
			$				$				$				$				$
Compensation			1,754				1,510				146				1,364				688
Severance			-				-				-				-				103
Share-based compensation costs			826				619				78				541				120
Total key management personnel compensation			2,580				2,129				224				1,905				911